Synaptogenix Inc (SNPX)

[Cyosol]

This has nothing to do with gene editing. Bryostatin 1 is a PKCe activator when used in low doses. It acts as a PKCe inhibitor in high doses.

https://en.wikipedia.org/wiki/PRKCE

The short version of the theory is that blood tests show Alzheimer's patients all have too low PKCe levels which is assumed to contribute to a neurotoxic environment in the brain that kills synapses (which are the things that connect brain cells with each other). Introduce a PKCe activator to the system and you now have a normal level of PKCe enzymes that among other things promotes the formation of new connections between brain cells and some other enzymes that destroy amyloid plaques and tau tangles.

Fragile X and other indications are assumed to be treatable by using the same method to generate new synapses to make up for the ones that the disease in question has destroyed or prevented from forming in the first place.

There's a link in the ibox where you can find decades of research papers explaining exactly what these enzymes are and how they work.

Low stock price is because of several failed trials and fundraisers diluting existing shareholders but further analysis shows there's a valid explanation for the results that can be taken care of in subsequent trials, such as Memantine blocking the drug, severe AD patients being too far gone and the previous trial length being too short to definitively show it works.

Several subgroups have shown statistically significant improvement over placebo but I personally think the market won't really care until they can post positive results in 2022/2023 and prove the last 2 trials were conducted the wrong way. Several reputable scientists agree there's potential here and assume the current trial should be enough to prove the drug actually works.

Also worth mentioning is that this is currently the only company in the world going after moderate-severe AD patients while other companies work on almost healthy patients suffering from cognitive impairment rather than actual dementia or AD.